ClinicalTrials.gg
CompletedNCT00362856Updated Sep 12, 2017

Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

A Phase 2 interventional study of larazotide acetate and Placebo in Celiac Disease, sponsored by 9 Meters Biopharma, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-09-12.

Sponsored by 9 Meters Biopharma, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2007, 19 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
25th of 68
80 · median 46
Started
2006
with 2 others
Phase 2
21 of 103
1 open now
Registered
2nd of 103
by date
Lead sponsor
8 of 103
9 Meters Biopharma, Inc.

Among the 103 studies in Celiac Disease with a site in United States, this one is the 25th largest by enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2006, is one of 21 in phase 2, and was the 2nd registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

This study was run to determine the safety, tolerance, and efficacy of multiple doses of larazotide acetate in subjects with celiac disease following a gluten challenge.

Read the detailed description

CLIN1001-004 was a randomized, double-blind, placebo controlled, dose-ranging, 7-arm, multicenter study with a gluten challenge. The objects were multiple dose safety and tolerance; efficacy (intestinal permeability [change in urinary LAMA ratio] and disease signs and symptoms) following gluten challenge.

Following a 21-day screening period, subjects were randomized to one of seven treatments groups: four groups received larazotide acetate (0.25 mg, 1 mg, 4 mg or 8 mg TID) along with an 800 mg gluten challenge, one group received placebo with an 800 mg gluten challenge, a safety control arm received the highest dose of larazotide acetate (8 mg TID) and gluten placebo and the last group received drug placebo and gluten placebo. The gluten challenge was administered as capsules (800 mg TID) with each main meal for a total of 2.4 g daily. Drug or drug placebo was administered TID 15 minutes prior to each main meal. Subjects received their assigned treatments for two weeks (Day 0 through Day 14) and came to clinic for a follow-up visit one week later (Day 21). Subjects remained on their gluten-free diet for the duration of the study.

03

Conditions studied

  • Celiac Disease

Browse trials for

Keywords

  • larazotide acetate
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have been diagnosed with celiac disease by for ≥ 6 months.
  • Have a Anti-Tissue Transglutaminase (tTG) ≤ 10 EU as measured by serology.
  • Must be on a gluten-free diet for at least the past 6 months.

Exclusion criteria

Exclusion Criteria:

  • Have any chronic active GI disease other than celiac disease (e.g., IBS, Crohn's, Colitis).
  • Have diabetes (Type 1 or Type 2).
  • Chronically consumes non-steroidal anti-inflammatory agents ("NSAIDs") or takes proton-pump inhibitors.
  • Consuming oral or immune suppressants.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Placebo comparator
    Placebo + Gluten

    placebo TID + gluten 800 mg TID administered orally in capsules

    Drug: Placebo

  • Placebo comparator
    Placebo + Gluten placebo

    placebo TID + gluten placebo TID administered orally in capsules

    Drug: Placebo

  • Other
    Larazotide acetate 8 mg + Gluten placebo

    Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules

    Drug: larazotide acetate

  • Active comparator
    Larazotide acetate 0.25 mg + Gluten

    Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules

    Drug: larazotide acetate

  • Active comparator
    Larazotide acetate 1 mg + Gluten

    Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules

    Drug: larazotide acetate

  • Active comparator
    Larazotide acetate 4 mg + Gluten

    Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules

    Drug: larazotide acetate

  • Active comparator
    Larazotide acetate 8 mg + Gluten

    Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules

    Drug: larazotide acetate

Interventions

06

What researchers measure

Primary outcomes

  1. To demonstrate the safety and tolerability of multiple, oral doses of larazotide acetate in celiac disease subjects that maintain a gluten-free diet.

    Safety endpoints assessed in this study were adverse events, vital signs, hematology, clinical chemistry, urinalysis and ECG

    Time frame: Safety measurements were performed at Screening and at Day 0, 7, 14, and 21 ('End of Study'). Any change from baseline value was calculated at each subsequent visit until "End of Study" (Day 21).

  2. To evaluate the efficacy of multiple dose levels of larazotide acetate in preventing intestinal permeability changes induced by gluten challenge

    The primary efficacy outcome was the Day 0-to-Day 14 change in urinary LAMA ratio ( a measure of intestinal permeability) as a response to gluten

    Time frame: On Days 0, 6, 13, and 20 subjects drank a solution of lactulose and mannitol. Subject's urine was collected during the day on Day 0 and overnight prior to subsequent visits and analyzed for LAMA recoveries via standardized methodologies.

Secondary outcomes

  1. Changes in daily and weekly reported health outcomes

    Health outcomes were assessed using a daily symptom diary; a weekly PGWBI and a weekly GSRS

    Time frame: Symptom diary - daily; PGWBI - weekly; GSRS - weekly

  2. Changes in urinary LAMA ratios between Day 0 to Day 7

    See Primary Outcome Measure No. 2

    Time frame: See Primary Outcome Measure No. 2

  3. Changes in urinary lactulose fractional excretion between Day 0 to Day 7 to Day 14

    See Primary Outcome Measure No. 2

    Time frame: See Primary Outcome Measure No. 2

  4. Changes in urinary mannitol fractional excretion between Day 0 to Day 7 to Day 14

    See Primary Outcome Measure No. 2

    Time frame: See Primary Outcome Measure No. 2

  5. Change in urinary nitrite / nitrate levels from Day 0 to Day 14

    Nitrite/nitrate levels were assessed for correlation to the measures of intestinal permeability

    Time frame: Day 0 and Day 14

  6. Change in anti-tTG levels from Screening to Day 21

    Changes between screening and Day 21 anti-tTG levels were assessed for correlation to the measures of intestinal permeability

    Time frame: Screening and Day 21

  7. Change in cell markers and cytokines from PBMCs

    Serum cytokine and cell surface marker determinations were assessed for correlation to the measures of intestinal permeability

    Time frame: Days 0, 7, 14 and 21

  8. Changes in zonulin level

    Serum zonulin levels were assessed for correlation to the measures of intestinal permeability

    Time frame: Days 0, 7, 14 and 21

07

Study locations

9 sites
  • Research Site
    Scottsdale, Arizona 85259, United States
  • San Diego, California 92123, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Morristown, New Jersey 07960, United States
  • Bismarck, North Dakota 58501, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Pittsburgh, Pennsylvania 15241, United States
  • Research Site
    Richmond, Virginia 23298, United States
08

References and documents

Publications

  • Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, Leon F, Arterburn LA, Paterson BM, Lan ZH, Murray JA. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012 Oct;107(10):1554-62. doi: 10.1038/ajg.2012.211. Epub 2012 Jul 24. PubMed 22825365 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2006 to primary completion in Mar 2007, 5 months.

Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2006
First posted
Aug 10, 2006
StartActual
Sep 13, 2006
Primary completionActual
Mar 6, 2007
CompletionActual
Mar 6, 2007
Last update
Sep 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00362856
Lead sponsor
9 Meters Biopharma, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2006
Start date
Sep 13, 2006
Primary completion
Mar 6, 2007
Completion
Mar 6, 2007
Last update
Sep 12, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larazotide acetate

Start the discussion